ABSTRACT: Intrauterine malnutrition is associated with increased susceptibility to chronic diseases in adulthood. Growth-restricted infants display a less favorable lipid profile already shortly postnatal. Maternal low protein diet (LPD) during gestation is a well-defined model of fetal programming in rodents and affects lipid metabolism of the offspring. Effects of LPD throughout gestation on physiologic relevant parameters of lipid metabolism are unclear. We aimed to determine effects of LPD on maternal-fetal cholesterol fluxes and fetal lipid synthesis in mice. Pregnant mice (dams) were fed with a control (18% casein) or an LPD (9% casein) from E0.5 onward. We quantified maternal-fetal cholesterol transport and maternal cholesterol absorption at E19.5 using stable isotopes. We determined fetal lipid biosynthesis at E19.5, after administration of (1-13 C)-acetate from E17.5 onward. LPD did not change fetal and maternal plasma and hepatic concentrations of cholesterol and triglycerides. LPD affected neither the magnitudes of maternal-fetal cholesterol flux, maternal cholesterol absorption, nor fetal synthesis of cholesterol and palmitate (both groups, ϳ14% and ϳ13%, respectively). We conclude that LPD throughout gestation in mice does not affect maternal-fetal cholesterol transport, fetal cholesterol or fatty acid synthesis, indicating that programming effects of LPD are not mediated by short-term changes in maternal-fetal lipid metabolism. (Pediatr Res 68: 10-15, 2010)
pidemiologic studies indicate that inadequate intrauterine nutrition is associated with increased susceptibility to develop chronic diseases in adulthood (e.g., diabetes, hypertension, and cardiovascular disease; "metabolic programming") (1) . Comparably, associations between small body size at birth and a less favorable lipid profile in adulthood have been described (2) (3) (4) . Already in the first postnatal days, growth restricted human infants display a more atherogenic lipid profile (increased plasma concentrations of triglycerides, total cholesterol, and LDL (C)) compared with infants with a birth weight appropriate for gestational age (5) .
Elevated plasma cholesterol is an established risk factor for the development of cardiovascular diseases later in life, however, insufficient cholesterol supply to the fetus impairs its development (6) . It was demonstrated that the fetus is capable of synthesizing a large fraction of the required cholesterol de novo (7) (8) (9) . As an independent source of cholesterol, maternal cholesterol can be transported to the fetal circulation (10) . Recently, it was shown that maternal-fetal cholesterol transport is influenced by maternal plasma cholesterol levels (11) . Interestingly, high maternal cholesterol levels increase the development of fetal aortic fatty streaks, as shown in human and animal studies (12, 13) . Hence, the metabolic condition of the mother during pregnancy can affect lipid metabolism in the offspring.
In humans, exposure to the Dutch Hunger Winter during late gestation is associated with increased adult obesity, glucose intolerance, and hypertension (14) . Several animal models were developed to mimic the caloric restriction during gestation. An established animal model to investigate metabolic consequences of gestational under nutrition in the offspring is a low protein diet (LPD) during gestation (15) .
Studies in rats have indicated that maternal protein restriction during gestation leads to features of the metabolic syndrome in adulthood, e.g., increased blood pressure (16), decreased insulin sensitivity, and alterations in lipid profile (17, 18) . In mice, maternal protein restriction during pregnancy impaired glucose clearance in the adult offspring (19) . Furthermore, experiments in mice showed that an LPD affected the renin-angiotensin system (important in the regulation of blood pressure) in the fetus already (20) .
Recently, we demonstrated in mice that maternal gestational protein reduced the expression of genes involved in lipid synthesis and cholesterol metabolism in the fetal liver (21) . Because the liver is a key player in regulating cholesterol and fatty acid homeostasis, we hypothesized that changes in fetal hepatic gene expression could translate into short-term ("acute") effects on cholesterol and fatty acid metabolism (such as maternal-fetal cholesterol flux and/or fetal cholesterol and lipid synthesis). If true, short-term effects on fetal lipid metabolism could be involved in the mechanism by which metabolic programming takes place. We aimed to determine the acute effects of maternal protein restriction during gestation on maternal-fetal cholesterol flux, on de novo fetal cholesterol synthesis, and on fatty acid synthesis in mice.
MATERIALS AND METHODS
Animals. C57BL/6J mice (age 20 Ϯ 1 wk) were obtained from Harlan (Horst, The Netherlands). Animals were housed in temperature-controlled rooms (23°C) with 12-h light cycling and free access to standard RMH-B mouse chow before the experiments (Arie Blok BV, Woerden, The Netherlands) and water ad libitum. Experimental procedures were approved by the local Ethical Committee for Animal Experiments of the University of Groningen.
Experimental procedures. All female rats received the control diet containing 180 g casein/kg (purified diet, 4400.18, Arie Blok BV, Woerden, The Netherlands) 2 weeks before mating. Virgin females were time mated using vaginal smears to assess their stage of estrous before introducing the male. After confirmation of mating by detection of a vaginal plug, the females were allocated to either the control diet or the isocaloric LPD (90 g casein/kg, purified diet 4400.17, Arie Blok BV, Woerden, The Netherlands) during the gestational period. The experimental diets are identical to the diets used by Langley-Evans et al. (22) and are described in detail in Table 1 . We originally planned an independent intervention study with a fourth experimental group (n ϭ 5) and own controls (n ϭ 5). However, the intervention was not executed, in contrast to the control treatment in the second group of five (control) mice. Because the design on the control group was identical, we considered it scientifically appropriate to include the control mice into this study, although it caused unequal distribution (n ϭ 10 for controls and n ϭ 5 for treated dams).
Animals were weighed every 2 d. On embryonic day 14.5 (E14.5), pregnant mice received an i.v. dose of 0.52 mg (1.265 mol) cholesterol-D 7 dissolved in Intralipid (20%, Fresenius Kabi, Den Bosch, The Netherlands) and an oral dose of 0.97 mg (2.30 mol) cholesterol-D 5 dissolved in mediumchain triglyceride oil. Weights of the dams ranged from 27.3 to 33.1 g at E14.5 of gestation and were not significantly different between the two dietary groups. From E17.5 onward both diets were supplemented with 10 mg/g [1-
13 C]-acetate (Isotec, Miamisburg, OH). Blood spots were collected from the tail on filter paper before administration of labeled cholesterol and acetate and daily from E14.5 onward to E19.5 of gestation. At E19.5, females were anesthetized with isoflurane and terminated by cardiac puncture. Figure 1 shows a schematic overview of the experimental setup.
Blood was collected in EDTA tubes. Liver and brain were snap frozen in liquid nitrogen. Fetuses were removed from uteri, weight and length were measured, and fetuses were killed and dissected. Blood samples were taken by exsanguination. Liver and brain of fetuses were collected, immediately snap frozen in liquid nitrogen and stored at Ϫ80°C. Sex of the fetuses was determined by PCR as previously described (23, 24) .
Analytical procedures. Cholesterol was extracted from blood spots and plasma according to Neese et al. (25) . Hepatic and brain lipids from mothers and pups and lipids from whole (complete) pups were extracted according to Bligh and Dyer (26) . Unesterified cholesterol from blood spots, plasma, and tissues were analyzed by gas chromatography quadrupole mass spectrometry (27) . Commercially available kits were used for the determination of total cholesterol in brain, liver, and plasma samples (Roche, Mannheim, Germany). Hepatic fatty acids from livers of mothers and fetuses were analyzed by gas chromatography quadrupole mass spectrometry according to Oosterveer et al. (28) . In short, lipids were extracted from livers and were hydrolyzed using HCL and acetonitrile. Fatty acids were extracted with hexane, after which the samples were derivatized using pentafluorobenzyl:triethanolamine:acetonitril solution. Enrichments of the PFB-derivatives of palmitate were measured by gas chromatography-mass spectrometry. The monitored ion were m/z 255-259 corresponding to the m0 -m4 mass isotopomers for C16:0.
Fractional cholesterol absorption measurement. Fractional cholesterol absorption was measured using an adapted plasma dual isotope ratio method (29) using blood spots obtained at 120 h after i.v. and oral administration of stableisotopically labeled cholesterol. For calculation of the fractional cholesterol absorption, the ratio of D 5 -cholesterol and D 7 -cholesterol in blood spots was divided by the ratio of D 5 -cholesterol and D 7 -cholesterol in the administered dose. The resulting value represents the fractional cholesterol absorption (27) .
Mass isotopomer distribution analysis (MIDA). To determine de novo cholesterol and palmitate synthesis, the MIDA approach was used (25, 30) . MIDA allows determination of the enrichment of the pool of acetyl-CoA precursor units that has entered newly synthesized cholesterol or palmitate molecules during the course of (1-13 C)-acetate administration. Analysis of the isotopomer pattern of these molecules allows for determination of the fraction (f) of newly synthesized cholesterol or palmitate, respectively, in plasma or tissue. All normalized mass isotopomer distributions measured by GC-MS (m 0 -m 0ϫ ) were corrected for the natural abundance of 13 C by multiple linear regression as described by Lee et al. (31) to obtain the excess fractional distribution of mass isotopomers (m 0 -m 0ϫ ) because of incorporation of the infused (1-13 C)-acetate as described in Ref. 28 . For determination of the absolute amount of newly synthesized hepatic palmitate, we multiplied f by the total amount of hepatic palmitate at the end of the experiment.
Statistics. We regarded the whole litter as one experimental unit, according to Festing (32) . All data are presented as means Ϯ SD. Statistical analyses were performed using SPSS 14.0 for Windows software (SPSS Inc., Chicago). All data analyzed using the Mann-Whitney U-test with a p Ͻ0.05 were considered significant.
RESULTS
Parameters in the control group. As stated above, the group size of the control mice was twice that of the experimental (low protein) intervention, based on the original design of two control groups of each n ϭ 5, undergoing identical (control) treatment. We analyzed whether results between the two n ϭ 5 control mice differed, but the parameters measured were virtually identical. Based on this observation, we pooled the data of the n ϭ 10 control mice.
LPD affects body weight in dams but not in fetuses. At E0.5, there was no difference in body weight of dams between both groups. At E19.5, dams on a LPD had lower body weights than control dams (Table 2 ). Food intake during gestation was not different until E17.5 (data not shown) but was lower in dams on a LPD between E17.5 and E19.5. There was no significant difference in the other parameters analyzed, including liver weight to body weight ratio of dams, litter size, body weight, body length, or liver weight to body weight ratio in fetuses (Table 2) . LPD does not affect total cholesterol concentrations in tissues. To investigate whether protein restriction diet during gestation influenced total cholesterol concentrations in dams and fetuses, we measured total cholesterol in tissues on E19.5. Figure 2A shows that total cholesterol levels in liver or brain in dams did not significantly differ between the two groups. In fetuses, protein restriction did not significantly affect total cholesterol levels in liver, brain, or whole body (the complete fetus; Fig. 2B ).
LPD does not affect maternal fractional absorption of cholesterol. We investigated whether the LPD quantitatively affected cholesterol absorption in the dam and cholesterol transport to the fetus during the last stage of gestation. Cholesterol absorption in dams was found to be 64 Ϯ 8% in control dams and 67 Ϯ 8% in low protein (NS).
LPD does not quantitatively affect maternal-fetal cholesterol transport. Maternal-fetal transport of cholesterol was determined by measurement of the fraction of labeled cholesterol in several tissues of dams and fetuses at E19.5. To determine whether the administration route to the dam influenced on cholesterol transport to the fetus, fractions of both D 5 and D 7 -labeled cholesterol in tissue and plasma were calculated. The rate of elimination of D 5 and D 7 cholesterol was measured every 24 h after administration (E14.5) until termination (E19.5) and did not significantly differ between dams on LPD or on control diet (data not shown). The fraction of orally administered D 5 cholesterol constituted ϳ0.5% of total cholesterol in livers and plasma of both groups. The fraction of orally administered D 5 cholesterol in brain was near detection level in dams of both groups (Fig. 3A) . In fetuses at E19.5, the fraction of D 5 cholesterol was measurable in liver, plasma, brain, and whole body albeit very low in both groups (Fig. 3B) .
The fraction of i.v.-administered D 7 cholesterol in plasma was higher in low protein dams compared with control dams (0.16 Ϯ 0.04% in control dams and 0.36 Ϯ 0.06% in low protein dams; p ϭ 0.028). In livers, this fraction was 2.2 Ϯ 0.2% in control dams and 2.8 Ϯ 0.2% in low protein dams. In brains of dams, the fraction of i.v.-administrated D 7 was below detection at E19.5 of gestation for both groups (Fig.  3C) . In fetuses at E19.5, the fraction of D 7 cholesterol was 1.0 Ϯ 0.1% in liver of control fetuses and 1.1 Ϯ 0.1% in liver of low protein fetuses. Fractions of D 7 cholesterol in plasma brain and whole body of fetuses were detectable, but below 0.5% in both groups (Fig. 3D) . No significant differences were found in the fractional enrichments of D 5 or D 7 cholesterol between control or low-protein dams or fetuses.
LPD does not quantitatively affect maternal or fetal lipid synthesis. All dams received (1-13 C)-acetate in the diet from E17.5 onward to investigate whether receiving an LPD during gestation would influence cholesterol or palmitate synthesis in dams and fetuses in the last stage of gestation. Precursor pool enrichments were ϳ9% for control dams and low protein dams at 24 and 48 h (Fig. 4A) , indicating steady-state and comparable levels of precursor pool enrichment in both groups. Fractional contribution of newly synthesized cholesterol was 11.9 Ϯ 0.4% for control dams and 9.2 Ϯ 2.7% for low protein dams at 24 h (NS) and 17.0 Ϯ 0.6% for control dams and 14.9 Ϯ 3.2% for low protein dams at 48 h (NS, Fig. 4B) .
We determined the incorporation of newly synthesized cholesterol in the fetus by calculating fractional newly syn- Fractional synthesis in fetuses was 12.6 Ϯ 0.5% in liver of control fetuses and 14.8 Ϯ 2.1% in liver of low protein fetuses, 13.1 Ϯ 2.1% in plasma of controls and 15.4 Ϯ 5.3% in plasma of low protein fetuses, 3.3 Ϯ 0.02% in brain of control fetuses and 4.0 Ϯ 0.4% in brain of low protein fetuses, 9.7 Ϯ 1.4% in whole body of control fetuses, and 10.7 Ϯ 1.2% in whole body of low protein fetuses (all NS, Fig. 5B ). No significant differences were found in fractional cholesterol synthesis between dams and fetuses on a control diet compared with dams and fetuses on an LPD.
Fractional and absolute de novo synthesis of palmitate (C16:0) in livers of dams and fetuses was calculated using MIDA. Fractional de novo synthesized palmitate was 23 Ϯ 2% in control dams and 23 Ϯ 5% in low protein dams. Fractional de novo synthesized palmitate was 12.3 Ϯ 0.4% in control fetuses and 14.8 Ϯ 1.0% in low protein fetuses (Fig.  6A) . Absolute de novo synthesis of palmitate was 7.3 Ϯ 1.4 mol/g in liver of control dams and 4.7 Ϯ 0.9 mol/g in liver of low protein dams (p 0.2). Absolute de novo synthesis of palmitate was 18.7 Ϯ 1.4 mol/g in liver of control fetuses and 25.0 Ϯ 2.8 /g in liver of low protein fetuses (Fig. 6B) . No significant differences considering fractional or absolute de novo synthesis of palmitate between the two groups of dams or fetuses were found.
DISCUSSION
A maternal LPD during the gestational period is a widely used animal model for intrauterine malnutrition to study the mechanisms underlying "metabolic programming." The purpose of using this diet during gestation is to mimic intrauterine malnutrition and its possible metabolic consequences. Most frequently, the LPD has been applied in rats in which gestational protein restriction resulted in impaired nephrogenesis and hypertension (33) , disturbed glucose tolerance, obesity, and alterations in lipid metabolism (17) in the adult offspring.
Several studies in mice demonstrate that maternal low protein during gestation leads to features of the metabolic syndrome in offspring. Male offspring from protein-restricted dams developed increased adiposity and glucose intolerance at adult age (34) . When fed with a high-fat diet, male offspring from protein-restricted dams show a higher increase in body weight, relative fat mass, hyperglycemia, hypercholesterolemia, and hyperleptinemia, compared with high-fed diet offspring from control dams (35) . Studying the metabolic effects of protein restriction during gestation in mice allows for extrapolation to studies on programming effects in different knock out mice. In the ApoE*3-Leiden mouse, a model for development of atherosclerosis, maternal protein restriction "aggravated" the dyslipidaemia and induced more severe atherosclerotic lesions in female adult offspring fed an atherogenic diet (36) . De novo fractional cholesterol synthesis in tissues of (A) dams and (B) fetuses. Ⅺ: control mice; f: mice receiving an LPD during gestation. 13 C-acetate was administrated in the diet and fractional synthesis was calculated using MIDA. n ϭ 5 for low-protein dams and 10 for control dams. Values represent the mean Ϯ SD.
Some human and animal studies showed that metabolic programming has differential effects in adult male and female offspring, albeit inconsistent. In this study, no differences between male and female pups in the studied parameters were observed.
We used a unique stable isotope method to determine maternal-fetal cholesterol fluxes and fetal lipid synthesis in mice. Administration of D 5 and D 7 -labeled cholesterol to the dam enabled us to distinguish between cholesterol of different maternal sources transported from dam to fetus. The simultaneous administration of 13 C-acetate to the dam allows determination of cholesterol and fatty acid synthesis in maternal and fetal organs.
In this study, the LPD slightly decreased maternal food intake and maternal weight, when compared with control diet. However, no differences in fetal weight or length were seen in protein-restricted fetuses compared with controls. The observation on fetal weight corresponds with several other studies using the same diet in rats (37, 38) .
In previous experiments in mice, we showed that protein restriction during gestation decreased mRNA expression of genes important in cholesterol transport and fatty acid synthesis in fetal livers (21) . These data supported the hypothesis that acute effects on lipid homeostasis could be related to the induction of programming. However, this study unequivocally demonstrates that maternal protein restriction during gestation does not induce acute, major quantitative changes in maternalfetal cholesterol transport, cholesterol biosynthesis, or fatty acid biosynthesis in the last stage of pregnancy in mice. Discrepancy between mRNA data and metabolic fluxes has been reported before, underscoring the notion that the "proof of the pudding" of reporting changes in mRNA and even protein activities is in measuring the relevant metabolic fluxes in vivo.
The fraction of i.v. administered cholesterol was significantly higher in plasma of the low protein dams compared with controls. However, this effect was not reflected in the total plasma cholesterol levels of dams or in the fractions of D 7 -labeled cholesterol in plasma or other tissues of pups. Therefore, we assume that the effect on i.v. fractions is of limited physiologic relevance.
We do realize that a theoretical limitation of this is the rapidly changing metabolism of dam and fetus during gestation, which constitutes metabolically a "nonsteady state" condition per definition. However, we feel that this limitation most likely applies equally for both the control and the low protein group and does not invalidate our main conclusions. Another realization involves the timing of our experiment to the late stage of gestation. Theoretically, the protein restriction diet could have influenced cholesterol flux to the fetus in the first stage of gestation. We do not have indications for this possibility as we did not find any differences in total cholesterol content in fetal organs in the last stage of gestation. Based on the results, it seems reasonable to assume that the effects of the maternal diet on cholesterol fluxes and/or on fetal hepatic lipid synthesis during the first stage of gestation are negligible. The presently used model does allow determination of effects of the maternal environment on maternal-fetal transport and on fetal cholesterol and fatty acid synthesis. The method could be applicable to studies investigating the influence of various maternal conditions such as maternal overnutrition or maternal diabetes on fetal lipid metabolism. In conclusion, programming effects of maternal protein restriction during gestation are not accompanied by immediate changes in fetal-maternal cholesterol transport or lipid synthesis in mice in the last stage of pregnancy. Apparently, programming effects of maternal LPD on lipid metabolism are mediated by more complex pathways than these acute effects.
